-
1
-
-
0025980747
-
Leflunomide (HWA 486), a novel immunomodulating compound for treatment of autoimmune disorders and reactions leading to transplantation rejection
-
Bartlett RR, Dimitrijevic M, Mattar T, Zielinski T, Germann T, Rude E, Thoenes GH, Kuchle CC, Schorlemmer HU, Bremer E, Finnegan A and Schleyerbach R. Leflunomide (HWA 486), a novel immunomodulating compound for treatment of autoimmune disorders and reactions leading to transplantation rejection. Agents and Actions 1991; 32: 10-21.
-
(1991)
Agents and Actions
, vol.32
, pp. 10-21
-
-
Bartlett, R.R.1
Dimitrijevic, M.2
Mattar, T.3
Zielinski, T.4
Germann, T.5
Rude, E.6
Thoenes, G.H.7
Kuchle, C.C.8
Schorlemmer, H.U.9
Bremer, E.10
Finnegan, A.11
Schleyerbach, R.12
-
2
-
-
0001162529
-
-
Lewis AJ, Furst DE (eds). Marcel Dekker: New York
-
Bartlett RR, Campion P, Musikic P, Schleyerbach R, Zielinski T and Schorlemmer HU. Nonsteroidal Anti-inflammatory Drugs: Mechanisms and Clinical Uses, Lewis AJ, Furst DE (eds). Marcel Dekker: New York, 1994; 349-366.
-
(1994)
Nonsteroidal Anti-inflammatory Drugs: Mechanisms and Clinical Uses
, pp. 349-366
-
-
Bartlett, R.R.1
Campion, P.2
Musikic, P.3
Schleyerbach, R.4
Zielinski, T.5
Schorlemmer, H.U.6
-
3
-
-
0029852104
-
Lefunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis
-
Bartlett RR, Brendel S, Zielinski T and Schorlemmer HU. Lefunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis. Transplantation Proceedings 1996; 28: 3074-3078.
-
(1996)
Transplantation Proceedings
, vol.28
, pp. 3074-3078
-
-
Bartlett, R.R.1
Brendel, S.2
Zielinski, T.3
Schorlemmer, H.U.4
-
5
-
-
0033764113
-
Leflunomide: Mode of action in the treatment of rheumatoid arthritis
-
Breedveld FC and Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Annals of Rheumatic Disease 2000; 59: 841-849.
-
(2000)
Annals of Rheumatic Disease
, vol.59
, pp. 841-849
-
-
Breedveld, F.C.1
Dayer, J.M.2
-
6
-
-
0029591467
-
The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis
-
Cherwinski HM, Cohn RG, Cheung P, Webster DJ, Xu YZ, Caulfield JP, Young JM, Nakano G and Ransom JT. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. Journal of Pharmacologv and Experimental Therapeutics 1995; 275: 1043-1049.
-
(1995)
Journal of Pharmacologv and Experimental Therapeutics
, vol.275
, pp. 1043-1049
-
-
Cherwinski, H.M.1
Cohn, R.G.2
Cheung, P.3
Webster, D.J.4
Xu, Y.Z.5
Caulfield, J.P.6
Young, J.M.7
Nakano, G.8
Ransom, J.T.9
-
7
-
-
0027279125
-
Leflunomide, a novel immunosuppressive agent. The mechanism of inhibition of T cell proliferation
-
Chong AS, Finnegan A, Jiang X, Gebel H, Sankary HN, Foster P and Williams JW. Leflunomide, a novel immunosuppressive agent. The mechanism of inhibition of T cell proliferation. Transplantation 1993; 55: 1361-1366.
-
(1993)
Transplantation
, vol.55
, pp. 1361-1366
-
-
Chong, A.S.1
Finnegan, A.2
Jiang, X.3
Gebel, H.4
Sankary, H.N.5
Foster, P.6
Williams, J.W.7
-
8
-
-
0030032806
-
The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase
-
Davis JP, Cain GA, Pitts WJ, Magolda RL and Copeland RA. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 1996; 35: 1270-1273.
-
(1996)
Biochemistry
, vol.35
, pp. 1270-1273
-
-
Davis, J.P.1
Cain, G.A.2
Pitts, W.J.3
Magolda, R.L.4
Copeland, R.A.5
-
9
-
-
0028853980
-
Measurement of the active leflunomide metabolite (A77 1726) by reverse-phase high-performance liquid chromatography
-
Dias VC, Lucien J, LeGatt DF and Yatscoff RW. Measurement of the active leflunomide metabolite (A77 1726) by reverse-phase high-performance liquid chromatography. Therapeutic Drug Monitoring 1995; 17: 84-88.
-
(1995)
Therapeutic Drug Monitoring
, vol.17
, pp. 84-88
-
-
Dias, V.C.1
Lucien, J.2
LeGatt, D.F.3
Yatscoff, R.W.4
-
10
-
-
85161747740
-
Clinical pharmacology/biopharmaceutics review. Arava® Leflunomide tablets; summary basis of approval equivalent
-
FDA. Study YU#204. FDA Summary Basis of Approval. NDA: 20-905
-
FDA. Study YU#204. Clinical pharmacology/biopharmaceutics review. Arava® Leflunomide tablets; summary basis of approval equivalent. FDA Summary Basis of Approval. NDA: 20-905, 1998.
-
(1998)
-
-
-
11
-
-
0029050136
-
Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide
-
Green S, Watanabe K, Braatz-Trulson J and Lou L. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochemical Pharmacology 1995; 50: 861-967.
-
(1995)
Biochemical Pharmacology
, vol.50
, pp. 861-967
-
-
Green, S.1
Watanabe, K.2
Braatz-Trulson, J.3
Lou, L.4
-
13
-
-
0027501428
-
Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide
-
Mattar T, Kochhar K, Bartlett RR, Bremer EG and Finnegan A. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Letters 1993; 334: 161-164.
-
(1993)
FEBS Letters
, vol.334
, pp. 161-164
-
-
Mattar, T.1
Kochhar, K.2
Bartlett, R.R.3
Bremer, E.G.4
Finnegan, A.5
-
14
-
-
0034469255
-
Bioanalytical method validation - A revisit with a decade of progress
-
Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, McKay G, Miller KJ, Patnaik RN, Powell ML, Tonelli A, Viswanathan CT and Yacobi A. Bioanalytical method validation - a revisit with a decade of progress. Pharmaceutical Research 2000; 17: 1551-1557.
-
(2000)
Pharmaceutical Research
, vol.17
, pp. 1551-1557
-
-
Shah, V.P.1
Midha, K.K.2
Findlay, J.W.3
Hill, H.M.4
Hulse, J.D.5
McGilveray, I.J.6
McKay, G.7
Miller, K.J.8
Patnaik, R.N.9
Powell, M.L.10
Tonelli, A.11
Viswanathan, C.T.12
Yacobi, A.13
-
15
-
-
12644249109
-
In vitro and in vivo effects of leflunomide, brequinar and cyclosporine on pyrimidine biosynthesis
-
Silva HT Jr, Cao W, Shorthouse RA, Loffler M and Morris RE. In vitro and in vivo effects of leflunomide, brequinar and cyclosporine on pyrimidine biosynthesis. Transplantation Proceedings 1997; 29: 1292-1293.
-
(1997)
Transplantation Proceedings
, vol.29
, pp. 1292-1293
-
-
Silva H.T., Jr.1
Cao, W.2
Shorthouse, R.A.3
Loffler, M.4
Morris, R.E.5
-
16
-
-
0031180972
-
In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in Mrl/MpJ-Ipr/lpr mice
-
Xu X, Blinder L, Shen J, Gong H, Finnegan A, Williams JW and Chong AS. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in Mrl/MpJ-Ipr/lpr mice. Journal of Immunology 1997; 159: 167-174.
-
(1997)
Journal of Immunology
, vol.159
, pp. 167-174
-
-
Xu, X.1
Blinder, L.2
Shen, J.3
Gong, H.4
Finnegan, A.5
Williams, J.W.6
Chong, A.S.7
|